Revenue: The sum of all revenue fields included for a company's operating activities.
Supernus Pharmaceuticals, Inc. (SUPN) had Revenue of $661.82M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$661.82M |
$73.86M |
|
$77.91M |
|
$583.91M |
|
$580.15M |
|
$81.67M |
|
$16.20M |
|
$97.87M |
|
$97.87M |
|
$73.86M |
|
$73.86M |
|
$73.86M |
|
$73.86M |
|
$81.67M |
|
$163.90M |
|
55.10M |
|
55.96M |
|
$1.34 |
|
$1.32 |
|
| Balance Sheet Financials | |
$686.07M |
|
$11.54M |
|
$682.00M |
|
$1.37B |
|
$292.40M |
|
-- |
|
$39.94M |
|
$332.34M |
|
$1.04B |
|
$396.80M |
|
$1.04B |
|
55.74M |
|
| Cash Flow Statement Financials | |
$171.95M |
|
$-189.87M |
|
$12.19M |
|
$75.05M |
|
$69.33M |
|
$-5.72M |
|
$27.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.23% |
|
12.34% |
|
12.34% |
|
24.77% |
|
14.79% |
|
11.16% |
|
$171.23M |
|
-- |
|
-- |
|
-- |
|
0.48 |
|
1.43 |
|
4.66 |
|
78.36 |
|
7.13% |
|
18.62% |
|
5.40% |
|
7.13% |
|
$18.58 |
|
$3.06 |
|
$3.07 |
|